NCT00025246View on ClinicalTrials.gov

Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

November 30, 2007

Conditions
Gastrointestinal Stromal Tumor
Interventions
DRUG

imatinib mesylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

27705

American College of Surgeons Oncology Group, Durham

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00025246 - Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery | Biotech Hunter | Biotech Hunter